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Graft-versus-host disease (GVHD) impairs immune reconstitution after allogeneic stem cell transplantation
(allo-SCT) and effective therapies aimed at restoring T cell counts in GVHD patients have yet to be developed.
During GVHD, CD4þ T cell reconstitution is particularly affected and current models hold that GVHD insult to
the peripheral lymphoid niche is responsible for this effect. Here, we show that naïve CD4þ T cell homeostatic
proliferation (HP) is lost during GVHD because of low systemic IL-7 and impaired dendritic cell (DC)
regeneration. We assessed factors involved in DC differentiation and found that although fms-like tyrosine
kinase 3 ligand (Flt3-L) levels were normal, stromal-derived factor-1a (SDF-1a) was diminished in the blood
of GVHD mice. Unlike Flt3-L treatment, the administration of SDF-1a speciﬁcally increased CD8aþ DC
numbers and did not worsen GVHD. Importantly, CD4þ T cell HP was enhanced only when IL-7 and SDF-1a or
Flt3L were coadministered, conﬁrming the crucial role of DCs and IL-7 in restoring CD4þ T cell regeneration
during GVHD. Altogether, our results indicate that CD8aþ DCs are part of the peripheral niche that controls
CD4þ T cell HP and that their depletion, combined with low systemic IL-7, explains how GVHD constrains
naïve CD4þ T cell reconstitution after allo-SCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) is the principal
complication of allogeneic stem cell transplantation (allo-
SCT) and occurs when alloreactive donor T cells recognize
differences in major and/or minor histocompatibility anti-
gens expressed by recipient cells [1]. Despite signiﬁcant
progress in clinical management of acute GVHD, its incidence
after allo-SCT is important and patients normally experience
chronic lymphopenia. Early after allo-SCT, the inﬂammatory
milieu presents a fertile ground for alloreactivity and thymic
insult resulting from GVHD is largely responsible for thymic
dysfunction and immune incompetence [2-4]. During thisdgments on page 1730.
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ty for Blood and Marrow Transplantation.period, peripheral mechanisms that regulate homeostatic
proliferation (HP) become essential to restore immunocom-
petence to the greatest extent [5,6].
Studies in mice and humans have demonstrated that
T cell receptor (TCR) stimulation and IL-7 signaling are both
essential for the maintenance and homeostatic cycling of
naïve T cells in the periphery [7-9]. After postnatal T cell
depletion, increased availability of IL-7 and selfepeptide
MHC complexes contribute to induce HP [10-13]. However,
HP of naive CD4þ T cells is inefﬁcient compared with that of
naive CD8þ T cells and normally results in chronic CD4
lymphopenia [6].
IL-7 is currently used in clinical trials to increase T cell
counts in lymphopenic patients but early results demon-
strate a greater beneﬁt on naïve CD8þ compared with naïve
CD4þ T cells [14,15]. TCR signaling is a major controlling
factor for IL-7 responsiveness of CD4 HP and in vivo modu-
lation of dendritic cells (DCs) by fms-like tyrosine kinase 3
ligand (Flt3-L) can substantially enhance HP of naïve T cells
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derived factor-1 alpha (SDF-1a) is important for DC homeo-
stasis but its mechanism of action remains largely unknown.
SDF-1a is a chemoattractive cytokine essential for the
homing and the retention of hematopoietic stem cells (HSCs)
inside the bone marrow (BM) [19]. Studies have demon-
strated that disruption of the SDF-1a/CXCR4 axis constrains
B cell lymphopoiesis and affects plasmacytoid dendritic cell
(pDC) differentiation and perhaps other DC subsets [20,21].
Thus, in addition to IL-7, DC homeostasis is likely to have a
substantial effect on the degree of CD4 HP after allo-SCT.
Recent insights into the biology of GVHD have demon-
strated that insult to the peripheral niche regulating T cell
homeostasis is perhaps the most important factor limiting
Tcell regeneration after allo-SCT [22,23]. Although IL-7 levels
are normally high during lymphopenia [11,12,17], studies
have demonstrated that the rise in systemic IL-7 after allo-
SCT is of short duration and IL-7 rapidly returns to lower
levels despite an incomplete immune reconstitution [24,25].
Moreover, it has been suggested that pDC maturation is
affected by GVHD and similarly to B cell lymphopoiesis,
insults to the BM microenvironment could account for this
effect [26-28]. Altogether, these ﬁndings support a model
wherein some elements of the peripheral niche required for
CD4 homeostatic expansion are dysfunctional during GVHD.
This study was conducted to evaluate the adverse effect of
GVHD on DCs and IL-7 and how these changes constrain
CD4þ T cell HP.
MATERIALS AND METHODS
Mice and Administration of IL-7, Flt3-L, and SDF-1a
Female C57BL/6.SJL (B6.SJL; H-2b, Ptprca Pep3b, CD45.1þ), C57BL/
6.129S7-Rag1tmMom/J (Rag/; H-2b, CD45.2þ) and (C57BL/6 X DBA2/J) F1
(B6D2F1; H-2b/d, CD45.2þ) mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME). Female C57BL/6.129S7-IL-7rtm1lmx/J (IL-7Ra/; H-2b,
CD45.2þ) were provided by Dr. CrystalMackall (NIH) and anti-HYCD4þ Tcell
(Marilyn) mice were provided by Dr. Olivier Lantz (Institut Curie). All ani-
mals were housed at the Maisonneuve-Rosemont hospital animal facility
and animal studies were performed in accordance with the Maisonneuve-
Rosemont Hospital animal care committee. Recombinant human IL-7
(rhIL-7) was supplied by Cytheris Inc (now RevImmune, Paris, France).
Vehicle (phosphate buffer saline; PBS) or rhIL-7 (10 mg) was administered to
mice for 7 days as a daily intraperitoneal (i.p.) injection. Recombinant hu-
man Flt3-L and SDF-1a were purchased from BioXcell (West Lebanon, NH)
and PeproTech (Quebec, Canada), respectively, and administered daily to
mice as an i.p. injection of 10 mg for 14 days.
Stem Cell Transplantation and GVHD
We used a “parent into F1” mouse model (B6/B6D2F1) for allogeneic
HSC stem cell transplantation using B6 mice as donors and B6D2F1 mice as
recipients. On day 0, 1 107 BM cells from either B6.IL-7Ra/ or B6.Rag/
donor mice (H-2b) were injected intravenously into lethally irradiated
(10 Gy) B6D2F1 recipients (H-2b/d) along with 1 106 puriﬁed T cells (T cell
enrichment kit, StemCell Technologies, Vancouver, Canada) from B6.SJL
mice (GVHD-causing T cells) or B6D2F1 mice (syngeneic T cells, no GVHD).
Mice were weighed every 3 days and monitored for clinical signs of GVHD. A
weight loss of 20% beyond day 14 after transplantation or signs of distress
(immobility, arched back, blepharospasm) were considered survival end-
points entailing euthanasia. For the generation of donor-derived DCs,
B6D2F1 recipientmice received 1107 BM cells intravenously from B6.Rag/
 donor mice. Six weeks later, hematopoietic cells of chimeric mice were
considered fully regenerated.
Cell Trace Violet Staining and Adoptive Transfer of Lymphocytes
Spleen and lymph nodes (LNs) from female Marilyn mice were ho-
mogenized and lymphocytes enriched by negative selection (T cell enrich-
ment kit, StemCell Technologies). Enriched T cells were suspended at
1  107 cells/mL in PBS and incubated for 15 minutes at room temperature
with 1 mL/mL of 5 mM cell trace violet (CTV, Invitrogen, Burlington, Canada).
Cells were washed twice in PBS and recipient mice received 1  106 CTV-
labeled T cells by i.v. injection. After 7 days, mice were sacriﬁced and
T cells in the spleen were analyzed for CTV content with a LSRII ﬂowcytometer (BD Bioscience, San Jose, CA). FlowJo software (TreeStar, Ashland,
OR) was used for all analysis.
DC Generation In Vitro
BM cells were ﬂushed from both femurs and tibias and 6  106 cells
(1  106/well, 6 wells per plate) were cultured for 7 days in complete RPMI
medium supplemented with 200 ng/mL of Flt3-L.
Histopathological Scoring and Microscopy
Tissues prepared for histology were ﬁxed in buffered 10% formalin
immediately after sampling, embedded in parafﬁn, cut in 5 mm sections,
and stained with hematoxylin and eosin according to standard methods.
Pictures from tissue sections were taken at room temperature using an
AxioCamMR3 camera mounted on an AxioImager Z2 microscope and
analyzed using the AxioVision software (Carl Zeiss, Toronto, Canada). Images
were acquired using a 10X/.3 numerical aperture objective. Histopatholog-
ical scoring on animals that had undergone transplantation was done by a
pathologist in a blinded fashion on parafﬁn-embedded colon, spleen, and
BM slides (see Supplemental Table 1 for scoring).
Flow Cytometry
Cells were resuspended at a density of 1  107 cells/mL in ﬂuorescent
activated cell sorter buffer and were incubated 30 minutes on ice with
diluted monoclonal antibodies and then washed and resuspended in ﬂuo-
rescent activated cell sorter buffer for immediate analysis. The following
monoclonal antibodies were used from BD Bioscience: PE-anti-Vb6 (RR4-7),
PerCPCy5.5-anti-Lineage cocktail; from BioLegend (San Diego, CA): PeCy7-
anti-CD4 (GK1.5); PeCy7-anti-CD8 (53-2.7); PerCPCy5.5-anti-CD45.1
(A20); FITC-anti-CD8 (5H10-1); PE-anti-CD11c (N418); PerCPCy5.5-anti-
CD11 b (M1/70); FITC-anti-B220 (RA3-6B2); FITC-anti-TCRb (H57-597), APC-
anti-H2-Kd (SF1-1.1), PeCy7-anti-CD117 (2B8), APCCy7-anti-Sca-1 (D7),
FITC-anti-CD16/32 (93); from eBioscience (San Diego, CA) : APC-anti-CD127
(A7R34), PE-anti-CD135 (A2F10), APC-anti-CD115 (AFS98); from Miltenyi
Biotec (Bergisch Gladbach, Germany): APC-Anti-PDCA-1 (JF05-1C2.4.1).
In Vivo Cytotoxicity Assay and T Cell Depletion
Spleens from B6, B6D2F1 and B6/B6D2F1 -chimeric mice were ho-
mogenized and DCs were isolated with the CD11c Positive Selection Kit
(StemCell Technologies). CD11c-positive cells were stained with 5 mM car-
boxyﬂuorescein succinimidyl ester (CFSE, Molecular Probes, Burlington,
Canada) or 5 mMCTV and resuspendedwith PBS at 1106 cells/mL at a ratio
of 1:1 prior to be injected i.v. into mice as speciﬁed. Thirty-six hours later,
mice were sacriﬁced and stained cells from the spleen were analyzed by
ﬂow cytometry. The absolute number of DCs was determined by gating on
CD11cþCFSEþor CD11cþCTVþ cells. For T cell depletion, mice that had un-
dergone transplantation were treated with 500 mg of anti-CD4 (GK1.5) and
anti-CD8 (2.43) at days þ28 and þ30 during GVHD, after allo-SCT.
ELISA
Brieﬂy, plasma was isolated at day þ35 after SCT by intracardiac punc-
ture of anesthetized mice and Flt3-L and SDF-1a levels were measured in
100 mL of one-half diluted plasma samples according to the manufacturer’s
protocol (R&D Systems, Minneapolis, MN).
Stromal Cell Isolation and Quantitative Real-Time PCR
BM from both femurs and tibias were ﬂushed and bones were cut into
little pieces and digested in dispase (.1%, Gibco, Burlington, Canada)þ type 1
collagenase (.25%, Sigma, St. Louis, MO) for 30 minutes at 37C. Stromal cells
were then ﬁltered through a 70 mm cell strainer and washed with complete
RPMI buffer (2% FBS, 1% Pen-Step). RNA was prepared from stromal and BM
cells using Trizol (Life Technologies, Burlington, Canada). Expression of IL-7,
Flt3-L, and SDF-1a mRNA was measured with an ABI-Prism 7500 Sequence
Detection system (Applied Biosystems, Burlington, Canada). RNA expression
for each sample was normalized to the expression of the housekeeping gene
Gapdh (encoding glyceraldehydes 3-phosphate dehydrogenase). Samples
were run in triplicates and RNA expression was determined using standard
curve method.
Statistical Analysis
Prism 5.0 (GraphPad Software, La Jolla, CA) was used for all statistical
analyses. Survival curves were plotted using Kaplan-Meier estimates and
compared by log-rank analysis. MannWhitneywas used to compare pairs of
data, and Kruskal-Wallis with Dunn’s post-test was used to compare 3 or
more groups. The speciﬁc tests used are described in the ﬁgure legends. A P
value less than or equal to .05 was considered signiﬁcant. Data are presented
as mean  SEM.
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GVHD Constrains CD4 HP
GVHD insult to the peripheral niche has been shown
to limit thymic-independent T cell regeneration but which
factor(s) is/are affected by GVHD remains unknown
[22,23,27]. Dendritic cells and IL-7 are both essential for
naïve T cells and accessibility to these factors could diminish
survival and HP of T cells during GVHD. Evaluation of HP in
GVHD hosts is difﬁcult because it can be confounded with
proliferation resulting fromTcell activation. Furthermore, HP
of naïve CD4þ T cells is typically inefﬁcient during lympho-
penia, which further complicates its evaluation during GVHD
(Supplemental Figure 1A). We have previously shown that
HP of CD4þ Tcells is augmented in IL-7Ra/mice [17] and toFigure 1. Loss of CD4 HP during GVHD. (A) Irradiated B6D2F1 recipients received 1 
syngeneic B6D2F1 (non-GVHD) puriﬁed splenic T cells. Twenty-eight days later, mice
assessed based on CTV dilution. (B) Weights of animals that had undergone transplant
line: syngeneic T cells þ IL-7Ra/ BM recipient; dark dotted line: GVHD Rag/ BM rec
percentage change from day 0 and were pooled from 3 experiments. (C) Survival
T cells þ IL-7Ra/ BM recipient; dark dotted line: GVHD Rag/ BM recipient; dar
(D) Total CD4þ or CD8þ T cells were counted in non-GVHD (white bars) and GVHD host
after transfer into GVHD or non-GVHD animals. Upper right: Anti-HY CD4þ T cells fro
proliferation assessed 1 week later. (F) Absolute number of anti-HY CD4þ T cells in GV
independent experiments, 3 mice per group. Results show mean  SEM. P values weamplify CD4 HP during lymphopenia, BM from female B6.IL-
7Ra/ mice was transplanted to female B6D2F1 recipients.
To induce GVHD, we added normal allogeneic female B6
T cells in the graft (Figure 1A).
To ensure that GVHD severity was not affected by lack of
IL-7Ra on hematopoietic cells, we compared GVHD in
female B6D2F1 mice grafted with BM cells from female
B6.IL-7Ra/ or B6.Rag/ (ie, IL-7Raþ/þ) mice. We found
that both GVHD groups experienced similar weight loss and
shorter survival time compared with mice receiving B6.IL-
7Ra/ BM and syngeneic B6D2F1 T lymphocytes
(Figure 1B,C). We then analyzed, in a blinded fashion, his-
topathology characteristics of acute GVHD at post-SCT
day þ35 and found equivalent alloreactive T cell107 HSCs from IL-7Ra/ or Rag/ mice with 1  106 allogeneic B6 (GVHD) or
received CTV-labeled anti-HY CD4þ T cells. Seven days later, proliferation was
ation were measured 3 times per week and averaged for the group (thin dotted
ipient; dark line: GVHD IL-7Ra/ BM recipient). Measures were compared as a
curve of mice from each group described in (A) (thin dotted line: syngeneic
k line: GVHD IL-7Ra/ BM recipient) Data was pooled from 3 experiments.
s (black bars) 35 days after allo-SCT. (E) Anti-HY CD4þ T cell proliferation 7 days
m GVHD animals were retransferred into secondary IL-7Ra/ recipients and
HD and non-GVHD hosts 7 days after transfer. Data are representative of 2 or 3
re determined by a Mann-Whitney test (**P  .01, ***P  .001).
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GVHD groups (Supplemental Figure 1B). T cell counts were
also similar between GVHD groups and signiﬁcantly
lower compared with non-GVHD mice (Figure 1D and
Supplemental Figure 1C,D). Together, our data demonstrate
that lack of IL-7Ra on hematopoietic cells does not signiﬁ-
cantly affect the severity of GVHD in this model.
The functionality of the peripheral niche was then
evaluated by transferring CTV-labeled nonalloreactive
naïve anti-HY CD4þ T cells (Marilyn) into GVHD or non-
GVHD hosts and assessing their HP (CTV dilution) 7 days
later (Figure 1A). It is important to stress that Marilyn T cells
used to evaluate the functionality of the peripheral niche in
GVHD mice cannot undergo T cell activation because they
are speciﬁc to the HY male antigen, which is absent in our
transplantation model (donors and recipients are female).
In addition, Marilyn T cells cannot elicit reactivity from
B6D2F1 T cells as they are derived from the C57BL/6 back-
ground (cells from B6D2F1 mice that express the H-2b/d
haplotype are tolerant to Marilyn cells expressing H-2b).
Thus, the use of females as donors and recipients insured
that proliferation of Marilyn cells would result from HP and
not T cell activation [17]. Although controls that underwent
transplantation with IL-7Ra/ BM cells and syngeneic
B6D2F1 T cells efﬁciently supported CD4 HP, proliferation of
Marilyn T cells was completely lost in GVHD hosts
(Figure 1E). Absence of HP was associated with diminished
recovery of anti-HY CD4þ T cells in the spleen (Figure 1F).
Finally, Marilyn T cells that failed to undergo HP in GVHD
animals could undergo HP upon transfer into secondary
nonirradiated IL-7Ra/ female recipients, conﬁrming
that GVHD insults to the peripheral niche are largely
responsible for lack of HP after allo-SCT (Figure 1E, upper
histogram).
Impaired DC Reconstitution and Low IL-7 Levels
Constrain CD4 HP during GVHD
Post-thymic survival of naïve CD4þ T lymphocytes de-
pends on ongoing stimulation between the TCR and self-
peptide MHC II complexes provided by DCs and a second
signal mediated by IL-7. Although the regeneration of donor-
derived CD11cþ cells occurred efﬁciently in non-GVHD mice
(full chimerism by post-ASCT day þ28, data not shown),
fewer DCs were found in GVHD hosts (Figure 2A,B). Specif-
ically, we found a signiﬁcant reduction in CD11cþCD11bþ and
CD11cþCD11b DCs as well as pDCs. We excluded again a
potential effect of the absence of IL-7 signaling on DC im-
mune reconstitution by repeating the same experiment with
B6.Rag/ and wild-type B6 BM and obtaining similar results
(Figure 2A and Supplemental Figure 1E-G). Finally, we
depleted CD11cþ DCs in IL-7Ra/CD11cDTR/B6D2F1
chimeric mice to conﬁrm the essential role of CD11cþ cells in
CD4 HP (Figure 2C).
We also examined IL-7 transcripts in BM and spleen
stromal cells and found diminished expression in GVHDmice
compared with that in non-GVHD hosts (Figure 2D). Given
that elevated systemic IL-7 can signal on stromal cells and
induce IL-7 mRNA down-modulation, we used an in vivo
bioassay based on IL-7 mediated down-regulation of IL-7Ra
on T cells to conﬁrm diminished systemic IL-7 in GVHDmice.
Congenic anti-HY CD4þ T lymphocytes transferred into
GVHD animals had much higher surface expression of IL-7Ra
than lymphocytes transferred into non-GVHD hosts, con-
ﬁrming low IL-7 levels in GVHD mice, despite profound
lymphopenia (Figure 2E). Together, our results support amodel wherein the absence of DCs combined with dimin-
ished systemic IL-7 contribute to impair HP of naïve CD4þ
T cells during GVHD.
Allorecognition and Myelosuppression Constrain DC
Regeneration during GVHD
The signiﬁcant reduction in donor-derived DC content
during GVHD could relate to their elimination by GVHD-
causing T cells or, like B lymphocytes, could result from
diminished production from HSCs [27]. We ﬁrst evaluated
the potential killing of mature DCs by alloreactive T cells
using an in vivo cytotoxicity assay inwhich we compared the
elimination of donor-derived DCB6/B6D2F1 and recipient
B6D2F1 DCs to control B6 DCs after adoptive transfer into
GVHD and non-GVHD hosts (Figure 3A). B6 DCs were used to
eliminate the possibility of nonspeciﬁc bystander killing, as
GVHD-causing T cells are normally tolerant to these cells. As
predicted, fewer B6D2F1 DCs were recovered from GVHD
hosts compared with control B6 DCs, conﬁrming the recog-
nition and elimination of recipient DCs by GVHD-causing
T cells (Figure 3B, upper panels). As for B6D2F1 DCs, less
donor-derived DCB6/B6D2F1 were recovered from GVHD
mice, conﬁrming the elimination of donor-derived DCs by
GVHD-causing T cells as well (Figure 3B, lower panels).
The ﬁnding that alloreactive T cells have the potential to
eliminate mature DCs raised the prospect that T cell deple-
tion could improve DC recovery in GVHD hosts. We, thus,
proceeded to deplete T cells during GVHD, ie, 28 days after
allo-SCT (Supplemental Figure 1H), and then monitored DC
recovery 2 months after. Although T cell depletion had no
impact on the number of DCs in control mice, we observed a
small but nonsigniﬁcant increase in CD11cþCD11bþ and
CD11cþCD11b DCs in T celledepleted GVHD animals
(Figure 3C). Together, our data support a model wherein
donor-derived DCs can be eliminated by alloreactive T cells,
but this mechanism is not the dominant factor limiting DC
regeneration during GVHD.
Systemic SDF-1a but not Flt3-L is Diminished in GVHD
Hosts
Because T cell depletion did not lead to a substantial in-
crease in DCs, we postulated that the diminution of donor-
derived DCs in GVHD mice could relate to an absence of DC
progenitors or an incapacity of these cells to differentiate
into mature DCs. As previously shown, the cellularity of the
BM was signiﬁcantly diminished, suggesting a global mye-
losuppression in GVHD mice (Supplemental Figure 2A). We
then studied common DC progenitors (CDP) and found fewer
of these cells in GVHD mice compared with those found in
non-GVHD hosts (Figure 4A). Consistent with the diminished
number of CDP in vivo, fewer DCs were generated from BM
cells of GVHD mice when cultured with Flt3-L (Figure 4B).
The role of Flt3-L is well known in DC development and given
its action on DC progenitors, we originally postulated that
Flt3-L production could be compromised during GVHD.
Surprisingly however, despite a signiﬁcant reduction in
Flt3-L transcripts in BM and spleen stromal cells, Flt3-L levels
were normal in the blood of GVHD mice, indicating that low
systemic Flt3-L is probably not the limiting factor that con-
strains DC regeneration during GVHD (Figure 4C,D). We also
looked at Flt3 receptor gene expression on Lin BM cells and
found diminished mRNA expression, probably because CDPs
are themselves reduced (Figure 4E).
Recent in vivo studies have indicated a critical role played
by the SDF-1a/CXCR4 axis in DC development [20]. SDF-1a is
Figure 2. GVHD constrains DC regeneration and IL-7 production. (A) DCs from the spleen were analyzed 35 days after allo-SCT by ﬂow cytometry. (B) Absolute
number of each DC subsets in the spleen of mice that underwent transplantation with IL-7Ra/ BM. (C) Histogram representative of CD4 HP after DC depletion.
B6D2F1 recipients underwent transplantationwith 10  106 IL-7Ra/CD11cDTR BM. Eight weeks later, 1 106 CTV-labeled anti-HY CD4þ T cells were transferred into
chimeric mice and diphteria toxin was given at days -1, þ1, and þ3. Proliferation was assessed by ﬂow cytometry 7 days after transfer. (D) Relative expression of IL-7
mRNA from the spleen and BM stromal cells of GVHD and non-GVHD B6D2F1 recipients. (E) Estimation of systemic IL-7 by transferring anti-HY CD4þ T cells into non-
GVHD (dotted line) and GVHD (black line) hosts and assessing IL-7Ra expression 24h later. Shaded histogram represent unstained control. Data are representative of 2
or 3 independent experiments; 3 mice per group. Results show mean  SEM. P values were determined by a Mann-Whitney test (**P  .01; ***P  .001).
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critical role in homing, maintenance, and survival of stem
cells within the BM [19,29-31]. RT-PCR analysis of SDF-1a
transcripts showed diminished gene expression in BM and
spleen stromal cells while the expression of CXCR4 on Lin
BM cells remained unaffected by GVHD (Figure 4F,G). Most
importantly, we found diminished systemic SDF-1a in the
blood of GVHD mice, raising the prospect that SDF-1a is
perhaps the limiting factor that hampers DC regeneration
during GVHD (Figure 4H).
Flt3-L and SDF-1a can Increase DC Numbers in GVHD
mice and Improve CD4 HP when Combined with IL-7
Therapy
It is well known that Flt3-L treatment can signiﬁcantly
increase DC numbers in mice [32] and humans [33] but, to
our knowledge, the capacity of SDF-1a to modulate DCcontent after allo-SCT has never been evaluated [34-36]. We
administered Flt3-L to GVHDmice and observed a signiﬁcant
increase in conventional CD11cþCD11b and CD11cþCD11bþ
DCs as well as pDCs (Figure 5A,B and Supplemental Figure 3).
We repeated the same experiment by administering SDF-1a
to GVHD mice and found a signiﬁcant increase in CD11cþ
DCs, this time limited to CD11cþCD11bCD8aþ DCs (CD8aþ
DCs) (Figure 5C-F and Supplemental Figure 3). Surprisingly,
weight loss and GVHD severity were diminished in SDF-1a
compared with those in PBS- and Flt3-Letreated mice
(Figure 5G,H).
To address the functionality of the peripheral niche
regenerated by Flt3-L or SDF-1a, we transferred CTV-labeled
anti-HY Marilyn cells into GVHD mice treated with these
factors and analyzed their proliferation 7 days later
(Figure 6A). Although the administration of Flt3-L or SDF-1a
could not restore naïve CD4 HP in GVHD mice (Figure 6B,C),
Figure 3. Elimination of donor-derived DCs by GVHD T cells. Donor, recipient, or donor-derived DCs were isolated and stained with CFSE or CTV before their transfer
into non-GVHD or GVHD animals. Mice were killed 36 hours after injection and DC numbers in the spleen were evaluated by ﬂow cytometry. (A) Schematic rep-
resentation of the experimental designwhere in vivo cytotoxicity toward DCs was assessed in GVHD and non-GVHD hosts. 1) B6D2F1 mice underwent transplantation
with B6 BM and donor-derived (B6/B6D2F1) DCs were isolated 6 weeks later. 2) CTV-labeled recipient (B6D2F1) or donor-derived (B6/B6D2F1) DCs were
transferred at the same ratio with CFSE-labeled donor (B6) DCs in non-GVHD or GVHD B6D2F1 recipients. (B) Representative dot plot of 3 independent experiments
comparing the recovery of recipient (B6D2F1) or donor-derived (B6/B6D2F1) DCs versus donor (B6) DCs in the spleen of non-GVHD or GVHD hosts. Histograms show
the ratio of DC numbers recovered after transfer in non-GVHD or GVHD recipients. Data are representative of 3 independent experiments. Three mice per group.
Results show mean  SEM. P values were determined by a Mann-Whitney test (*P  .05; **P  .01). (C) Mice that had undergone transplantation were treated with
anti-CD4 and anti-CD8 28 days after SCT. Spleen dendritic cells were evaluated 2 months after T cell depletion by ﬂow cytometry ( : SYN; : SYN T cell depleted;
: GVHD; : GVHD T cell depleted). Data are representative of 2 independent experiments. Three mice per group. Results show mean  SEM. P values were
determined by a Kruskal-Wallis test followed by a post-hoc Dunn’s test (*P  .05; **P  .01).
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could signiﬁcantly improve naïve CD4 HP (Figure 6B-D).
Importantly, IL-7 alone was insufﬁcient for CD4 HP, con-
ﬁrming the critical role of CD11cþ DCs in this process.
Nonetheless, more anti-HY CD4þ T cells were recovered from
IL-7etreated mice, indicating that IL-7 can increase T cell
survival despite lack of HP [18] (Figure 6D). Altogether, our
data demonstrate that loss of naïve CD4 HP during GVHD
relates in part to diminished DCs and low IL-7 levels.
DISCUSSION
In this study, we identify 3 key elements at which GVHD
impairs thymic independent CD4 immune reconstitution.
We ﬁrst show that HP of nonalloreactive naïve CD4þ T cells is
diminished because DC counts and systemic IL-7 are low in
GVHD hosts. Second, GVHD insults induce chronic dysfunc-
tion of the BM microenvironment, which limits DC produc-
tion even after GVHD-causing T cells are removed. Finally, we
show that the administration of SDF-1a can increase DC
counts and, when administered with IL-7, improve HP of
naïve CD4þ T cells after allo-SCT.
In humans, studies have demonstrated that DC counts can
be diminished during GVHD but the potential impact on CD4þ
T cell homeostasis has never been fully understood [26,37].
The effects of alloreactivity on DC homeostasis are probably
multiple, but here we found that GVHD-causing T cells caneliminate mature DCs and induce damage to the BM micro-
environment, resulting in impaired DC production from
donor HSCs. DCs expressing the relevant MHC-allopeptide
complexes represent obvious targets for GVHD-causing
T cells and their elimination could limit overwhelming T cell
activation [38]. Surprisingly, the removal of alloreactive Tcells
during GVHD failed to restore DC counts, which remained
below normal levels for several months after lymphodeple-
tion (Figure 3C and observation by S-D. Gauthier). In addition,
the observation that GVHD HSCs undergo normal differenti-
ation into DCs when transferred into non-GVHD hosts ismore
consistent with chronic damage to the BM microenviron-
ment, acting as a key limiting factor for DC regeneration after
allo-SCT (data not shown). We cannot, however, exclude the
possibility that donor-derived DCs were eliminated by radi-
oresistant recipient natural killer cells.
Although factors involved in DC differentiation have not
been entirely elucidated, studies have indicated a role for
Flt3-L and SDF-1a in DC homeostasis [39,40]. During GVHD,
both transcripts were signiﬁcantly diminished in the BM but
only systemic SDF-1a was decreased in the blood. Flt3-L can
be produced by activated T lymphocytes, which could
compensate for diminished Flt3-L production by stromal
cells [41]. Therefore, it seems paradoxical to invoke limiting
amounts of Flt3-L to explain the lack of DC regeneration
in GVHD hosts, unless systemic Flt3-L is not physiologically
Figure 4. Common DC progenitors as well as SDF-1a levels are diminished in GVHD mice. (A) Representative dot plot analysis and absolute counts of common DC
progenitors (CDP) in non-GVHD and GVHD BM 35 days after transplantation. CDP were gated as Linc-kitintSca-1CD16/32CD135þCD115þ cells. (B) BM cells
(6  106) from non-GVHD and GVHD mice were cultured in vitro for 7 days with Flt3-L to generate DCs. Percentages represent percent of CD11cþMHC IIþ on total
cells. (C) Flt3-L mRNA relative expression in BM and spleen stromal cells 35 days after SCT. (D) Flt3-L levels in plasma of animals that had undergone transplantation
35 days after SCT. (E) Flt3 (CD135) mRNA relative expression in Lin HSC of non-GVHD and GVHD mice 35 days after SCT. (F) SDF-1amRNA relative expression in BM
and spleen stromal cells 35 days after SCT. (G) CXCR4 mRNA relative expression in Lin BM cells of non-GVHD and GVHD mice 35 days after SCT. (H) SDF-1a levels in
plasma of animals that had undergone transplantation 35 days after SCT. Data are representative of 2 or 3 independent experiments. Three mice per group. Results
show mean  SEM. P values were determined by a Mann-Whitney test (*P  .05; **P  .01; ***P  .001).
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HP and, although its level is normally high during lympho-
penia [11,12], we found low IL-7 levels in GVHD mice
(Figure 2D, E). Similar ﬁndings were made in humans who
had undergone transplantation and IL-7 consumption by T
lymphocytes has been invoked to explain low IL-7 levels
[24,25]. Importantly, however, it is unlikely that IL-7 con-
sumption by GVHD-causing T cells explains such decrease
because most T cells are activated during GVHD and do notexpress signiﬁcant IL-7Ra on their surface [42]. A negative
feedback loop on IL-7eproducing cells can occur when sys-
temic IL-7 is high enough to signal on stromal cells but we
excluded this possibility as low systemic IL-7 combined with
diminished IL-7 mRNA production by stromal cells is more
consistent with alterations to IL-7 producing cells (Figure 2C,
D). IL-7, Flt3-L, and SDF-1a are all produced by stromal cells
and during GVHD, fewer mesenchymal stem cells were
recovered frommice (Supplemental Figure 2B) [43-45]. Thus,
Figure 5. Flt3-L andSDF-1a increaseDCs inGVHD. (A)Representativedotplot analysisofnon-GVHDorGVHDmice treated for14dayswith Flt3-LorPBS startingatdayþ28
after SCT. (B) Absolute counts of CD11cþ, CD11cþCD11bþ, CD11cþCD11b, and mPDCAþ cells after Flt3-L treatment ( : SYN; : GVHD þ PBS; : GVHD þ Flt3-L). (C)
Representative dot plot analysis of non-GVHD and GVHD mice treated for 14 days with SDF-1a or PBS starting at day þ28 after SCT. (D) Absolute counts of CD11cþ,
CD11cþCD11bþ, CD11cþCD11b, andmPDCAþ cells after SDF-1a treatment ( : SYN; : GVHDþ PBS; : GVHDþ SDF-1a). (E) Absolute counts of CD11cþCD11bCD8aþ
cells after SDF-1a treatment. (F) Comparative histogram of CD11cþ absolute cell counts after Flt3-L or SDF-1a treatments. (G) Bodyweight of GVHDmice treatedwith PBS
(C, versus SDF-1a; P¼ .018), Flt3-L (;, versus SDF-1a; P¼ .012) or SDF-1a (-) and non-GVHDmice (:, versus SDF-1a; P¼ .004). P values were determined by a Mann-
Whitney test. (H) Histopathology score (sum of all organs) of non-GVHD and GVHDmice treatedwith PBS, Flt3-L, or SDF-1a. Data are representative of 2 or 3 independent
experiments. Three to5micepergroup.Results showmean SEM.P valuesweredeterminedbyaKruskal-Wallis test followedbyapost-hocDunn’s test (*P .05; **P .01).
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lymphoid organs contribute to the impairment of the CD4
peripheral niche.Approaches to accelerate lymphocyte reconstitution
after allo-SCT have demonstrated that the beneﬁt on T cell
regeneration is frequently offset by excessive GVHD [46-48].
Figure 6. Flt3-L or SDF-1a combined to IL-7 can restore CD4 homeostatic proliferation during GVHD. (A) Irradiated wild-type B6D2F1 mice received 1  107 HSCs
from IL-7Ra/ mice with 1  106 allogeneic B6 (GVHD) or syngeneic B6D2F1 (non-GVHD) puriﬁed splenic T cells. Twenty-eight days later, mice were treated with
Flt3-L or SDF-1a for 14 consecutive days. At day þ35, mice received CTV-labeled anti-HY CD4þ T cells. Mice were then treated with daily IL-7 injections. At day þ42,
mice were sacriﬁced and CD4þ T cell HP was evaluated by ﬂow cytometry. (B) Representative histograms of CTV dilution of anti-HY CD4þ T cells in different groups of
treated animals. (C) Percentage of divided Marilyn CD4þ T cells 7 days after transfer. (D) Absolute count of anti-HY CD4þ T cells recovered from the spleen 1 week after
transfer in GVHD mice treated with PBS, IL-7, Flt3-L þ IL-7, or SDF-1aþIL-7. Data are representative of 2 to 3 independent experiments. Three mice per group. Results
show mean  SEM. P values were determined by a Kruskal-Wallis test followed by a post-hoc Dunn’s test (*P  .05; **P  .01; ***P  .001).
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most DC subsets are increased by the treatment (Figure 5
and Supplemental Figure 3). In contrast, SDF-1a did not
worsen GVHD, perhaps because its effect is restricted to
CD8aþ DCs. Interestingly, CD8aþ DCs have an intrinsic
inability to activate CD4þ T cells and are poor inducers of
alloreactivity [49,50]. Such characteristics are perhaps
important for preventing unwanted T cell activation during
homeostatic stimulation of naïve CD4þ T cells. Finally, we
cannot exclude a potential effect of SDF-1a on T cells
themselves, as SDF-1a signaling can affect their homing and
location, as well as their function [51,52]. Additional studies
are necessary to clarify the mechanism of SDF-1a and
perhaps determine whether this chemokine, or CXCR4
agonists, could be used to improve CD4 regeneration and
GVHD after allo-SCT.
IL-7 has also been implicated in GVHD and when
administered early after allo-SCT, it can expand anti-host
reactive T cell precursors and aggravate GVHD [48,53,54]. In
this work, we initiated IL-7 therapy at day þ35 after allo-SCT,
when most T cells are activated and express undetectable
levels of IL-7Ra, which likely explains why GVHD severity
was not affected by IL-7 treatment (not shown). Our data
demonstrate that improvement of CD4 HP during GVHD re-
quires not only IL-7 therapy but also the administration offactors regulating DC differentiation and production. Inter-
estingly, in the setting of T celledepleted allo-SCT, IL-7
therapy can improve immune reconstitution of T cells, in part
due to partial recovery of thymopoiesis but also because DC
immune reconstitution in the periphery is robust [42,55].
Despite our ability to induce HP of CD4 in GVHD hosts, levels
of proliferation remained low compared with non-GVHD
controls (Figure 6B). Such difference perhaps relates to the
dosing and administration schedule of SDF-1a, physiologic
IL-7 levels, access of naïve CD4þ T cells to secondary
lymphoid organs, and damage to lymphoid organs them-
selves. Additional studies are needed to establish the optimal
therapeutic condition of SDF-1a for maximal effect on naïve
CD4þ T cell expansion.
In summary, lymphocyte reconstitution represents a
major challenge in the ﬁeld of allo-SCT because immune
intervention to accelerate T cell regeneration can worsen
GVHD. Our study shows that GVHD induces chronic damage
to the BM microenvironment, which in turn impairs the
regeneration of the lymphoid niche that regulates peripheral
CD4 homeostasis. This study also implicates SDF-1a as a key
regulator of CD8aþ DCs and identiﬁes this subset as part of
the peripheral niche controlling CD4 HP. Finally, we propose
that future therapies aimed at restoring CD4þ T cell counts in
GVHD hosts should include, in addition to IL-7, SDF-1a or
S.-D. Gauthier et al. / Biol Blood Marrow Transplant 21 (2015) 1721e17311730CXCR4 agonist to promote the regeneration of DC subset(s)
involved in the homeostasis of CD4þ T cells.
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